紅日藥業(300026.SZ)2019年度淨利潤預增80%-110%
格隆匯1月21日丨紅日藥業(300026.SZ)公佈,預計2019年度歸屬於上市公司股東的淨利潤3.79億元-4.43億元,同比增長80%-110%。
報告期內,公司以戰略為引領,堅持以經營業績為導向,各項經營計劃順利完成,主營業務穩步增長。公司預計2019年度實現歸屬於上市公司股東的淨利潤較上年同期增長80%-110%。
1、公司中藥配方顆粒業務加強市場開拓,通過產業扶貧加快產業線佈局,營業收入保持穩定增長。
2、本年度公司主力產品血必淨注射液循證醫學研究取得重大突破,“血必淨治療重症肺炎的多中心隨機對照臨牀研究”成果在國際重症醫學權威雜誌《重症醫學,Critical Care Medicine,CCM》發表,研究結論證實血必淨顯著降低重症肺炎患者病死率8.8%。同時,血必淨注射液成功納入《2019版國家醫保藥品目錄》。
3、本年度公司實施第二期股權激勵計劃,分兩期解鎖,本年預計確認股權激勵費用2464萬元。
4、公司將根據本年度經營情況及未來經營計劃對商譽進行減值測試,如果減值測試結果表明資產的可收回金額低於其賬面價值的,按其差額計提減值準備並計入減值損失。
5、公司本年度的非經常性損益金額約為1300-1500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.